TrialCancer communications (London, England)2025

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Jianli Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.